Jianjun Cheng

发表

G protein-coupled receptors: structure- and function-based drug discovery

Suwen Zhao, Qing Liu, Ming-Wei Wang, 2021, Signal Transduction and Targeted Therapy.

Design and Synthesis of (2-(5-Chloro-2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)cyclopropyl)methanamine as a Selective Serotonin 2C Agonist.

B. Roth, A. Kozikowski, P. Giguère, 2015, Tetrahedron letters.

Dual-acting antitumor agents targeting the A2A adenosine receptor and histone deacetylases: Design and synthesis of 4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine derivatives.

Hualiang Jiang, K. Wüthrich, Cheng-ying Xie, 2022, European journal of medicinal chemistry.

Enhancing the Signaling of GPCRs via Orthosteric Ions

Shuguang Yuan, H. Vogel, H. C. S. Chan, 2020, ACS central science.

Design and Discovery of Functionally Selective Serotonin 2C (5-HT2C) Receptor Agonists.

B. Roth, T. Kenakin, A. Kozikowski, 2016, Journal of medicinal chemistry.

Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT2C) receptor agonist without 5-HT2B agonism.

B. Roth, Guiping Zhang, A. Kozikowski, 2019, European journal of medicinal chemistry.

Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties.

Yushe Yang, Jianjun Cheng, Wenhao Hu, 2019, Journal of medicinal chemistry.

Structure-based discovery of nonhallucinogenic psychedelic analogs

Zhipu Luo, Jinsong Li, Jianjun Cheng, 2022, Science.

We Need 2C but Not 2B: Developing Serotonin 2C (5‐HT2C) Receptor Agonists for the Treatment of CNS Disorders

A. Kozikowski, Jianjun Cheng, 2015, ChemMedChem.

Structural basis for strychnine activation of human bitter taste receptor TAS2R46

Suwen Zhao, Zhi-jie Liu, Lijie Wu, 2022, Science.

The unconventional activation of the muscarinic acetylcholine receptor M4R by diverse ligands

Suwen Zhao, Lijie Wu, T. Hua, 2022, Nature Communications.

Long Residence Time at the Vasopressin V2 Receptor Translates into Superior Inhibitory Effects in Ex Vivo and In Vivo Models of Autosomal Dominant Polycystic Kidney Disease.

Ying Sun, Peng-Cheng Wang, Jianjun Cheng, 2022, Journal of medicinal chemistry.

Revisit ligand-receptor interaction at the human vasopressin V2 receptor: A kinetic perspective.

L. Peletier, D. Guo, Xudong Cao, 2020, European journal of pharmacology.

Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.

B. Roth, Guiping Zhang, A. Kozikowski, 2017, Journal of medicinal chemistry.

Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects in Open Field, Prepulse Inhibition, and Cognition Models

R. Rodriguiz, W. Wetsel, B. Roth, 2021 .

Momilactone and Related Diterpenoids as Potential Agricultural Chemicals.

J. Duan, C. Che, Jianjun Cheng, 2018, Journal of agricultural and food chemistry.

Identification of natural products as novel ligands for the human 5-HT2C receptor

R. Stevens, Guisheng Zhong, Suwen Zhao, 2018, Biophysics reports.

2-Phenylcyclopropylmethylamine Derivatives as Dopamine D2 Receptor Partial Agonists: Design, Synthesis, and Biological Evaluation.

Jianjun Cheng, Ruiquan Liu, Wenzhong Yan, 2021, Journal of medicinal chemistry.

5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology

David E. Gloriam, John D. McCorvy, Bryan L. Roth, 2018, Cell.

Pheromone Receptors Help Cnaphalocrocis medinalis Avoid Competition in Rice Fields

Jianjun Cheng, Yongjun Du, Yongle Zhang, 2021, bioRxiv.

Haloperidol bound D2 dopamine receptor structure inspired the discovery of subtype selective ligands

Zhipu Luo, Jianjun Cheng, Fen Nie, 2020, Nature Communications.

5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice

R. Rodriguiz, W. Wetsel, B. Roth, 2017, Neuropsychopharmacology.

Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A2A adenosine receptors and histone deacetylases

Jianjun Cheng, Ruiquan Liu, Jinfeng Zhang, 2023, Chinese Chemical Letters.

Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents.

Hualiang Jiang, Guisheng Zhong, Suwen Zhao, 2021, Journal of medicinal chemistry.

Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists

K. Wüthrich, Wenwen Duan, Jianjun Cheng, 2020, Pharmaceuticals.

Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.

J. McCorvy, Jianjun Cheng, Wenzhong Yan, 2018, Journal of medicinal chemistry.

Optical-Controlled Kinetic Switch: Fine-Tuning of the Residence Time of an Antagonist Binding to the Vasopressin V2 Receptor in In Vitro, Ex Vivo, and In Vivo Models of ADPKD.

Jianjun Cheng, Wenzhong Yan, Xiaoke Gu, 2022, Journal of medicinal chemistry.

Design and Synthesis of Triazole-Containing HDAC Inhibitors That Induce Antitumor Effects and Immune Response.

Cheng-ying Xie, Wenwen Duan, Jianjun Cheng, 2023, Journal of medicinal chemistry.

Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties

Zhipu Luo, Jianjun Cheng, Fen Nie, 2021, Nature Neuroscience.

Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.

Giulio Vistoli, Claire M Schmerberg, Bryan L Roth, 2015, Journal of medicinal chemistry.

Transformation of a Dopamine D2 Receptor Agonist to Partial Agonists as Novel Antipsychotic Agents.

Jianjun Cheng, Ruiquan Liu, L. Tan, 2023, Journal of medicinal chemistry.

Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands.

Xi-Ping Huang, Jian Sun, Suwen Zhao, 2020, Journal of medicinal chemistry.

Haloperidol bound D2 dopamine receptor structure inspired the discovery of subtype selective ligands

Zhipu Luo, Jianjun Cheng, Fen Nie, 2020, Nature Communications.

Azide‐Masked Resiquimod Activated by Hypoxia for Selective Tumor Therapy

N. Shen, Zhaohui Tang, Jianjun Cheng, 2023, Advanced materials.

Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.

R. Rodriguiz, Xi-Ping Huang, W. Wetsel, 2016, Journal of medicinal chemistry.

Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties

Zhipu Luo, Jianjun Cheng, Huan Wang, 2021, Nature Neuroscience.

Biochemical analysis of the interactions of IQGAP 1 C-terminal domain with CDC 42

Jianjun Cheng, Dan Zhang, Lianbao Ma, 2012 .

Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants.

Jianjun Cheng, Sheng Wang, Wenwen Duan, 2023, Chemical reviews.

Design and Synthesis of Novel GPR139 Agonists with Therapeutic Effects in Mouse Models of Social Interaction and Cognitive Impairment.

Jianjun Cheng, Huan Wang, Zhi-Jie Liu, 2023, Journal of medicinal chemistry.

Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.

Zhi-jie Liu, Wenwen Duan, T. Hua, 2021, European journal of medicinal chemistry.

Adenosine A2A Receptor (A2AAR) Ligand Screening Using the 19F-NMR Probe FPPA.

K. Wüthrich, Jianjun Cheng, Jinfeng Zhang, 2023, Journal of the American Chemical Society.